SpringWorks Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2020 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
SpringWorks Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2020 to Q3 2024.
  • SpringWorks Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 14.3 %, a 0.07% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 14.3 -0.01 -0.07% Sep 30, 2024
Q2 2024 15 +2.37 +18.7% Jun 30, 2024
Q1 2024 16.1 +3.9 +32.1% Mar 31, 2024
Q4 2023 15.2 +3.96 +35.3% Dec 31, 2023
Q3 2023 14.3 +4.6 +47.5% Sep 30, 2023
Q2 2023 12.7 +4.63 +57.7% Jun 30, 2023
Q1 2023 12.2 +5.85 +92.6% Mar 31, 2023
Q4 2022 11.2 +5.89 +110% Dec 31, 2022
Q3 2022 9.68 +5.23 +118% Sep 30, 2022
Q2 2022 8.02 +3.93 +96% Jun 30, 2022
Q1 2022 6.32 +2.54 +67.3% Mar 31, 2022
Q4 2021 5.33 +1.7 +46.8% Dec 31, 2021
Q3 2021 4.45 +0.64 +16.8% Sep 30, 2021
Q2 2021 4.1 +0.66 +19.2% Jun 30, 2021
Q1 2021 3.78 Mar 31, 2021
Q4 2020 3.63 Dec 31, 2020
Q3 2020 3.81 Sep 30, 2020
Q2 2020 3.44 Jun 30, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.